GlassScriptPhysician profile
Nathan T Kenyon
NPI 1851651657
$24,206.65
in general payments reported to CMS, 2019-2025
12 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 88% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,291 · 2020: $4,254 · 2021: $3,926 · 2022: $7,315 · 2023: $1,083 · 2024: $2,301 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,894 · Travel and Lodging: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,894.11 |
| Travel and Lodging | $1,526.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13,914.30 | 2019-2025 | Proclaim, Eterna, Octrode |
| Medtronic, INC. | $6,713.57 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Medtronic USA, INC. | $2,639.68 | 2019-2020 | |
| Nevro Corp. | $247.34 | 2019-2020 | |
| Stryker Corporation | $242.09 | 2025 | Optablate |
| Abbvie INC. | $126.87 | 2022-2025 | |
| Covidien LP | $111.34 | 2019 | |
| Aurinia Pharma U.S., INC. | $73.70 | 2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $50.61 | 2025 | Acthar |
| Amgen INC. | $36.23 | 2024 | Krystexxa |
| Grt US Holding, INC. | $28.90 | 2022 | |
| Averitas Pharma INC. | $22.02 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Kenyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.